Bristol-Myers Squibb Company
Spiroheptane salicylamides and related compounds as inhibitors of rock
Last updated:
Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
13 Jan 2017
Issue date:
7 Apr 2020